Docket N0.: 069804—0349
`
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`Yukari HATAOKA
`
`: Customer Number: 20277
`'
`
`Application No.2 13/627,811
`
`: Confirmation N0.: 5929
`
`Filed: September 26, 2012
`
`: Art Unit: 1656
`
`For: Method For Immobilizing Glucose Oxidase On A: Examiner: C. M. Kam
`Self—Assembled Monolayer
`
`RES QUEST FOR CORRECTED APPLICATION DATA SHEET
`AND CORRECTED OFFICIAL FILING RECEIPT
`
`Office of Initial Patent Examination’s Filing Receipt Corrections
`Commissioner for Patents
`
`PO. Box 1450
`
`Alexandria, VA 22313—1450
`
`Madam:
`
`Applicant hereby is submitting a corrected Application Data Sheet (ADS) and Request for
`Corrected Official Filing Receipt in the above-identified patent application. There was an error in
`the Customer Number in the Correspondence Information, Representative Information and the
`Assignee in the Application Data Sheet and the Assignment For Published Patent Application and
`Power of Attorney Customer Number in the Filing Receipt, specifically, change the Assignee to
`read PANASONIC HEALTHCARE HOLDINGS CO., LTD. and Customer Number to read
`
`20277 in the ADS and Filing Receipt. Applicant additionally requests that all pertinent US. Patent
`and Trademark Office records relating to the subject application be changed to reflect this
`correction.
`
`Applicant believes no fee is due with this request. However, if a fee is due, please charge
`our Deposit Account No. 50—0417, under Order No. 0698040349 from which the undersignedIS
`authorized to draw.
`»
`
`
`Respect ‘ 11y submitted,
`
`/MCD
`Err WILL & EMERY LLP
`
`500 North Capitol Street, NW
`Washington, DC 20001
`Phone: (202) 756—8372 MEF2mem
`Facsimile: (202) 756—8087
`Date: April 8, 2015
`
`DMfiUS 601031344 0698040349
`
`Mic, ael E. Fogarty
`egistration No. 36,139
`
`PIease recognize our Customer No. 20277 as
`0Iir correspondence address.
`
`
`
`

`

`UNITED STATES PATENT AND TRADEMARK OFFIGE
`
`
`
`
`
`13/627,811
`
`
`09/26/2012
`I652
`1310
`
`53080
`MCDERMOTT WILL & EMERY LLP
`The women Building
`500 North Capitol Street, NW.
`WASHINGTON, DC 20001
`
`UNITED STATES DEPARTMEVT OF COMMERCE
`United States Patent and Trademark Office
`AddressCOlVIL/IISSIONER FOR PATENTS
`PO Box I450
`Alcxamlnafi’ijgmia 223134450
`\WNI'.usptogm
`
`0698040149
`
`IND CLAIMS
`
`
`3
`CONFIRMATION NO. 5929
`FILING RECEIPT
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`
`Date Mailed: 10/22/2012
`
`Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination
`in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the
`application must include the following identification information: the US. APPLICATION NUMBER, FILING DATE,
`NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the
`changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit
`any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply
`to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections
`
`lnventor(s)
`
`Applicant(s)
`
`Yukari HATAOKA, Osaka, JAPAN;
`
`PaHQSGRIGGQTPGFatierh-GsakawAPAN'
`V ' H '7
`"
`Assignment For Published Patent Application
`Panasonic Corporation, Osaka: JAPAN— PANASONI C HEALTHCARE HOLDINGS CO .
`TOKYO ,
`JAPAN
`
`
`
`I LTD .
`
`Power of Attorney: The patent practitioners associated with Customer Number 53080“
`
`2 O 2 7 7
`
`Domestic Priority data as claimed by applicant
`This application is a CON of PCT/JP2011/004127 07/21/2011
`
`Foreign Applications (You may be eligible to benefit from the Patent Prosecution Highway program at the
`USPTO. Please see http://wwwusptogov for more information.)
`JAPAN 2010—234314 10/19/2010
`
`Request to Retrieve ~ This application either claims priority to one or more applications filed in an intellectual
`property Office that participates in the Priority Document Exchange (PDX) program or contains a proper Request to
`Retrieve Electronic Priority Application(s) (PTO/SB/38 or its equivalent). Consequently, the USPTO will attempt
`to electronically retrieve these priorin documents.
`
`If Required, Foreign Filing License Granted: 10/17/2012
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 13/627,811
`Projected Publication Date: 01/31/2018
`Non-Publication Request: No
`
`page 1 013
`
`

`

`Early Publication Request: No
`Title
`
`METHOD FOR iMMOBlLlZiNG GLUCOSE OXIDASE ON A SELFtASSEMBLED MONOLAYER
`
`Preliminary Class
`
`435
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a US. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT—member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a US. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents”) for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800786—9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the US. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the US. Government hotline at 1‘866-999-HALT (1 866—999—4158).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`QBANIED.
`
`if the phrase "IF REQUIRED, FORElGN FiLiNG
`The applicant has been granted a license under 35 U.S.C. 184,
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`page 2 of 3
`
`

`

`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730—774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 5 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`
`
`SelectUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage, facilitate, and accelerate business investment. To learn more about why the USA is the best
`country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`page 3 of 3
`
`